In osteoporosis treatment, for instance, the bisphosphonate alendronate could be used as a bone resorption inhibitor and a bone-targeting molecule; if conjugated with Cathepsin K-targeting siRNA to disrupt resorption, it may increase the overall effectivity of osteoporosis treatment [63]. The gene discussed is CTSK; the disease is osteoporosis.